hrp0089rfc9.4 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2018

REplacement of MAle mini-Puberty in Neonates and Children with Micropenis and Cryptorchidism due to Hypogonadotropic Hypogonadism: Results of the ‘REMAP’ Study ISRCTN13007297

Papadimitriou Dimitrios T , Chrysis Dionysios , Nyktari Georgia , Zoupanos George , Liakou Eleni , Papadimitriou Anastasios , Mastorakos George

Background: Hormonal replacement in boys with congenital Hypogonadotrophic Hypogonadism (HH) as well as hormonal repair of bilateral cryptorchidism and micropenis remain a challenge in pediatric endocrinology.Methods: In the «REMAP» study ISRCTN13007297 eight neonates and infants, all with bilateral cryptorchidism in intra-abdominal position and micropenis (≤2 cm), with absence of neonatal male-mini puberty were treated for 3 months with ...

hrp0089rfc9.6 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2018

Can Neuroimaging Predict Endocrine Morbidity in Congenital Hypothalamo-Pituitary (H-P) Disorders?

Cerbone Manuela , Guemes Maria , Wade Angie , Improda Nicola , Dattani Mehul T

Background: Few studies have described the phenotypic spectrum of Septo-Optic Dysplasia (SOD). The aim of this study was to evaluate the range of H-P structural abnormalities and the endocrine morbidity of children with SOD and related disorders.Methods: Retrospective longitudinal single centre study of children with SOD (n:171), Multiple Pituitary Hormone Deficiency (MPHD) (n:53) and Optic Nerve Hypoplasia (ONH) (n:35).<p class="ab...

hrp0089rfc13.4 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2018

Gain in Predicted Adult Height Using the Combination of an LHRH Analogue and an Aromatase Inhibitor in Early Maturing Girls with Compromised Growth for 2 yrs or Until the Age of 11 is Maintained and Further Improved by Aromatase Inhibitor Monotherapy: Results on Final Height of the ‘GAIL’ Study ISRCTN11469487

Papadimitriou Dimitrios T , Dermitzaki Eleni , Papagianni Maria , Kleanthous Kleanthis , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy to increase predicted adult height (PAH) in girls. Our previously published GAIL study (J Endocrinol Invest. 2016 Apr;39(4):439–46) has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in girls with early puberty +1.21 SDS (+7.51 cm) compared to inhibition of puberty alone +0.31 SDS (+1.92 cm), P=...

hrp0089p3-p033 | Bone, Growth Plate &amp; Mineral Metabolism P3 | ESPE2018

A 13 Year-Old Boy Diagnosed as Osteogenesis Omperfecta with Normal Bone Mineral Density

Tınastepe Tuba , Filibeli Berna Eroğlu , Catlı Gonul , Dundar Bumin Nuri

Osteogenesis imperfecta is a hereditary connective tissue disease developing based on the structure or synthesis impairment of type 1 collagen and proceeding with diffuse osteoporosis, fragility, fractures and deformities in bones. Bone mineral density can be at normal or even high levels particularly especially in type I and XIII. Here, a 13 year-old boy diagnosed as osteogenesis imperfecta with normal bone mineral density was presented and treatment results were shared. A 13...

hrp0089p2-p073 | Diabetes &amp; Insulin P2 | ESPE2018

A Novel Mutation in Phka2: Idiopathic Ketotic Hypoglycaemia May Represent Mild Gsdixa

Flejsborg Anne Benner , Brusgaard Klaus , Pedersen Carsten , Frederiksen Anja L , Christesen Henrik T

Background: Idiopathic ketotic hypoglycaemia (IKH) is an exclusion diagnosis and the most common cause of hypoglycaemia in childhood. Glycogen Storage disease (GSD) type IX comprises one quarter of all GSD’s. GSDIXa, encoded by PHKA2, is the most frequent subtype.Objective: To investigate whether IKH may be undiagnosed GSDIXa.Methods: Hospital file review and next generation sequence 29 gene GSD-panel.<p class="ab...

hrp0089p1-p105 | Fat, Metabolism and Obesity P1 | ESPE2018

Effect of a Melanocortin-4 Receptor (MC4R) Agonist, Setmelanotide, on Obesity and Hyperphagia in Individuals Affected by Alström Syndrome

Han Joan C , Fiedorek Fred T , Hylan Michelle , Folster Cathy , Hiwot Tarekegn

Background: Alström syndrome (AS) is a rare genetic ciliopathy characterized by severe early-onset obesity, hyperphagia, retinal dystrophy, hearing loss, and cardiomyopathy. Rodent studies suggest that cilia play an important role in the leptin-MC4R pathway, which regulates energy balance and body weight. Setmelanotide, a peptide agonist of the MC4R, has led to weight loss in individuals affected by other rare genetic obesity disorders resulting from dysfunction in this p...

hrp0089p1-p187 | Growth &amp; Syndromes P1 | ESPE2018

A Novel Deadly Variant in the TP53 Gene Causing Li-Fraumeni Syndrome. The Importance of Clinical Awareness and the Contribution of Molecular Diagnosis in Active Prevention Within Families with Multiple Tumor Incidents at a Young Age

Bothou Christina , Spyridis Georgios P , Papantonatos Dionysios A , Stratakis Constantine A , Papadimitriou Dimitrios T

Background: Li-Fraumeni Syndrome (LFS) is an autosomal dominant hereditary cancer syndrome associated with germline pathogenic variants in in the TP53 gene and high risk of a broad range of early-onset malignancies. The 70-77% of LFS associated tumors are: breast cancer, soft-tissue sarcoma, brain tumor, osteosarcoma and adrenocortical carcinoma. However, ovarian, pancreatic and gastrointestinal track tumors are also LFS-related. The patients with LFS are at risk for a second ...

hrp0089p2-p290 | Multisystem Endocrine Disorders P2 | ESPE2018

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year Old Girl

Bothou Christina , Alexopoulos Alexis , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George , Papadimitriou Dimitrios T

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of...

hrp0089p1-p201 | Pituitary, Neuroendocrinology and Puberty P1 | ESPE2018

Anastrozole is Safe as Monotherapy in Early Maturing Girls with Compromised Growth, Further Improving Gain in Predicted Adult Height by the Initial Combination Therapy of an LHRH Analogue and an Aromatase Inhibitor: Results from the ‘Gail’ Study ISRCTN11469487

Dermitzaki Eleni , Kleanthous Kleanthis , Papagianni Maria , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios , Papadimitriou Dimitrios T

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy, except for Mc Cune-Albright syndrome and autonomous ovarian cysts, to increase predicted adult height (PAH) in girls, mainly due to the theoretical concern of hyperandrogenism. Our previously published GAIL study [J Endocrinol Invest. 2016 Apr;39(4):439–46] has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in g...

hrp0089lb-p16 | Late Breaking P1 | ESPE2018

Successful Treatment of Alopecia Totalis with Calcitriol and Paricalcitol in Two Girls Aged 3 and 7-Years

Papadimitriou Dimitrios T , Bothou Christina , Dermitzaki Eleni , Kleanthous Kleanthis , Karkavitsas Konstantinos , Mastorakos George , Papadimitriou Anastasios

Backgound: Alopecia areata (AA) or Alopecia Totalis (AT) is an autoimmune disease directed at the hair follicle, either limited to patchy hair loss over the scalp (focalis), or as total loss of scalp hair (totalis) or as total loss of both scalp and body hair (universalis). Management can be challenging, and despite multiple treatment modalities, no therapy still stands. While localized AA may respond well to topical corticosteroids, many patients require more aggressive secon...